Selux Diagnostics, which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, has raised $50 million in Series C financing.

The Series C round was led by RA Capital Management, with participation from Sands Capital, Schooner Capital and Northpond Ventures.

Selux's Next-Generation Phenotyping (NGP) platform provides rapid, high-throughput, fully automated AST results, enabling same-shift susceptibility testing of up to 50 antibiotics in parallel. The platform is driven by Selux's proprietary technologies, which differentiate antibiotic-induced bacterial growth modes through the interplay of novel biochemical assays and cutting-edge artificial intelligence.